Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - a double-blind, placebo-controlled study
Guglielmetti S, Mora D, Gschwender M, Popp K
Published in Alimentary Pharmacology & Therapeutics
Abstract
Multicentre double-blind placebo-controlled randomised trial of Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome.
Key Findings
B. bifidum MIMBb75 reduced global IBS symptoms in 57% of patients versus 21% on placebo, with significant improvements in pain, distension and quality of life over 4 weeks.
Conclusions
A single well-characterised B. bifidum strain can meaningfully relieve IBS symptoms.
Limitations
Four-week duration, industry sponsorship, single-strain result not generalisable to other bifidobacteria.
Supplements Studied
B. bifidum MIMBb75 reduced global IBS symptoms in 57% of patients versus 21% on placebo, with significant improvements in pain, distension and quality of life over 4 weeks.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.